#United States #Los Angeles #Securities Fraud #Capricor Therapeutics #SBS Law Firm

Investment Opportunities in Capricor Therapeutics' Securities Fraud Lawsuit

Investors holding shares in Capricor Therapeutics, Inc. are presented with a significant opportunity to participate in a class action lawsuit against the company for alleged securities fraud. This legal action is spearheaded by the national shareholder rights litigation firm, Schall, Brown & Schwartz LLP (SBS).

Background of the Case

Founded in 2016, Capricor Therapeutics specializes in advanced medical therapies, with a focus on developing treatments for cardiovascular diseases. However, the company's journey has not been without controversy. According to recent reports, the firm has been accused of making false and misleading statements regarding its lead product, Deramiocel, which has drawn scrutiny from investors.

Allegations

The allegations stem from Capricor’s misleading disclosures related to clinical trial data analysis methods. Specifically, during an important class action period—spanning from December 17, 2025, to July 26, 2026—the firm allegedly altered the statistical analysis plan for clinical trial results without prior approval from the FDA. This lack of transparency regarding the effectiveness of Deramiocel has raised serious concerns among shareholders.

The complaint highlights that Capricor’s public communications were materially misleading, which may have caused undue financial damage to investors once the truth about the product's approval prospects emerged. By failing to provide accurate and complete information, Capricor’s actions have led to significant distrust within the investment community.

Important Dates

Shareholders with vested interests in Capricor are encouraged to act before the key deadlines. Investors have until September 28, 2026, to express their intention to be considered as lead plaintiffs. Interestingly, participation as a lead plaintiff is not mandatory for claiming any potential recoveries linked to this case.

Contact Information for Investors

SBS Law is inviting all affected investors to reach out and discuss their rights. Investors may contact Brian Schall or David Schwartz at their Los Angeles office for a no-obligation consultation at 310-301-3335 or through email at [email protected]. Investors can also visit SBS’s website for additional guidance.

Join the Action

As of now, the class in this litigation is not yet certified, meaning that until certification is achieved, investors are considered absent class members. Nevertheless, those who have incurred losses related to Capricor’s alleged fraudulent practices are encouraged to join the action in order to recover their financial setbacks.

Why Choose SBS?

Schall, Brown & Schwartz LLP has earned a strong reputation for representing investors globally and is adept in managing securities class action lawsuits. The firm’s founding partners bring a wealth of experience and a passionate commitment to advocating for investor rights.

By participating in this lawsuit, shareholders can hold the company accountable for its alleged misrepresentations and seek reparations for their losses. Given the unfolding developments in this litigation, affected investors should not miss the chance to exercise their rights. Stay informed and take action to protect your investments in Capricor Therapeutics.